OverviewSuggest Edit

Genprex is a gene therapy company developing treatments for cancer and diabetes. Its cancer therapies are based upon a technology platform, including its lead drug candidate, Oncoprex immunogene therapy, or Oncoprex, for non-small cell lung cancer that consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects.

TypePublic
Founded2009
HQWest Lake Hills, TX, US
Websitegenprex.com

Latest Updates

Employees (est.) (Mar 2020)8(+15%)
Revenue (FY, 2019)$0
Share Price (Oct 2021)$2.3(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Genprex

Rodney Varner

Rodney Varner

Chairman, President & Chief Executive Officer
Catherine M. Vaczy

Catherine M. Vaczy

Executive Vice President, General Counsel & Chief Strategy Officer
Michael T. Redman

Michael T. Redman

Executive Vice President & Chief Operating Officer
Ryan M. Confer

Ryan M. Confer

Chief Financial Officer
Shannon Inman

Shannon Inman

Vice President of Global Clinical Operations
William E. Gannon

William E. Gannon

Vice President of Regulatory Affairs
Show more

Genprex Office Locations

Genprex has offices in West Lake Hills and Austin
West Lake Hills, TX, US (HQ)
3300 Bee Caves Rd 650 227
Austin, TX, US
One Congress Plaza, 100 Congress Ave Ste. 2000
Show all (2)

Genprex Financials and Metrics

Genprex Revenue

USD

Net income (FY, 2020)

(17.9m)

EBIT (FY, 2020)

(18.0m)

Market capitalization (22-Oct-2021)

108.5m

Closing stock price (22-Oct-2021)

2.3

Cash (31-Dec-2020)

27.3m
Genprex's current market capitalization is $108.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

3.0m11.4m8.7m10.6m

R&D expense

289.9k971.4k2.0m7.3m

Operating expense total

3.3m12.4m10.7m17.9m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

634.1k5.9m1.7m1.7m3.2m1.9m4.1m2.2m1.4m

R&D expense

51.6k113.0k489.7k508.0k502.0k467.3k1.5m2.2m1.4m

Operating expense total

686.6k6.0m2.2m2.2m3.7m2.4m5.6m4.4m2.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

161.3k8.6m2.0m27.3m

Accounts Receivable

8.8k9.3k655.0127.0

Prepaid Expenses

23.5k236.9k171.7k384.6k

Inventories

801.8k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

24.5k12.0m10.3m6.9m4.5m2.5m23.1m22.1m21.1m

Accounts Receivable

838.09.2k10.7k85.085.0

Prepaid Expenses

33.1k538.6k370.4k100.3k445.9k258.7k69.6k1.1m966.1k

Inventories

801.8k882.6k894.0k686.3k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.3m)(12.4m)(10.7m)(17.9m)

Depreciation and Amortization

3.2k5.9k13.1k22.8k

Accounts Payable

545.3k(443.1k)141.2k(247.3k)

Cash From Operating Activities

(2.2m)(6.8m)(6.9m)(13.9m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(694.0k)(6.8m)(8.9m)(2.2m)(5.9m)(8.2m)(5.6m)(9.9m)(12.7m)

Depreciation and Amortization

947.02.1k3.8k2.9k6.0k9.5k5.4k11.1k16.8k

Accounts Payable

519.9k(328.5k)(63.7k)(88.8k)582.2k189.9k202.1k(254.3k)(114.8k)

Cash From Operating Activities

(203.7k)(3.3m)(4.8m)(1.6m)(3.2m)(5.2m)(4.5m)(8.0m)(10.0m)
USDFY, 2017

Financial Leverage

2.9 x
Show all financial metrics

Genprex Operating Metrics

Feb, 2014Q2, 2017

Patent Applications

2

Patents Issued

30

Phase I Patients Enrolled

5728
Show all operating metrics

Genprex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Genprex Online and Social Media Presence

Embed Graph

Genprex Company Culture

  • CEO Rating

    A+

    90/100

Learn more on Comparably

Genprex News and Updates

Proactive news headlines including Nextleaf Solutions, Genprex, Ready Set Gold, Sigma Lithium and Esports Entertainment

New York , June 23, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

Proactive news headlines including Genprex, INDVR Brands, QC Copper and Gold and Hillcrest EnergyTechnologies

New York, April 12, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for…

Genprex Announces Formation of Clinical Advisory Board

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development prog…

Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will present at the Virtual Investor Conference Small and Microcap Showcase on February 4, 202…

Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment

Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers.”
Show more

Genprex Blogs

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline

Genprex to Participate in September Investor Conferences

Presentations to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Genprex to Participate in a Monthly CEO Roadshow Webinar Series

Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Genprex’s Novel Immunogene Therapy in Lung Cancer Highlighted in Key Opinion Leader Event

Genprex’s lead drug candidate, REQORSA™ Immunogene Therapy that uses our proprietary, non-viral ONCOPREX® Nanoparticle Delivery System was highlighted in a Key Opinion Leader event hosted by Alliance Global Partners (AGP) for their institutional customers.

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer
Show more

Genprex Frequently Asked Questions

  • When was Genprex founded?

    Genprex was founded in 2009.

  • Who are Genprex key executives?

    Genprex's key executives are Rodney Varner, Catherine M. Vaczy and Michael T. Redman.

  • How many employees does Genprex have?

    Genprex has 8 employees.

  • Who are Genprex competitors?

    Competitors of Genprex include Oragenics, NexImmune and Qu Biologics.

  • Where is Genprex headquarters?

    Genprex headquarters is located at 3300 Bee Caves Rd 650 227, West Lake Hills.

  • Where are Genprex offices?

    Genprex has offices in West Lake Hills and Austin.

  • How many offices does Genprex have?

    Genprex has 2 offices.